scholarly journals Anemia in patients with diabetes mellitus

2007 ◽  
Vol 60 (5-6) ◽  
pp. 225-230 ◽  
Author(s):  
Nada Dimkovic
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
Work Capacity ◽  
Stage I ◽  
Dominant Factor ◽  
Diabetic Patients ◽  
Type I ◽  
Cross Sectional ◽  
Diabetic Renal Disease ◽  
Cardiovascular Morbidity And Mortality

Introduction: Anemia is more common and pronounced in patients with diabetic, than in patients with non-diabetic renal disease. While several factors contribute to its pathogenesis, the failure of the kidney to increase erythropoietin in response to falling hemoglobin appears to be the dominant factor. The most frequent complications of anemia in diabetic patients include decreased quality of life and work capacity and increased cardiovascular morbidity and mortality. Material and Methods: This cross-sectional multicenter study included a total of 539 patients with type I (~20%) and type II diabetes (~80%) classified into five stages according to the glomerular filtration rate. Results Diabetic nephropathy appears in stage I, and progresses in all patients to the stage V (p=0.045). The presence of anemia progressively increased from stage I to stage V (from 60% to 100%, p=0.008). Only 62% of patients with anemia were treated (mainly with iron) and only 3.4% received erythropoietin treatment. Hypertension was present in 90% of patients in stage I and in 100% of patients in stage V nephropathy. The presence of heart failure increased from 0% (stage I) to 51% (stage IV, p=0.03). Around 62% of patients were referred to a nephrologist, and according to the logistic regression model, renal failure and presence of anemia were significant predictors of patients' referral to nephrologist. Conclusion: In a primary care setting, anemia is a frequent finding, even in the very beginning of diabetic renal disease. Currently available guidelines for management of anemia are not followed; this may explain high percentage of patients with heart failure in pre-dialysis stage. Early referral to a nephrologist and regular follow-up by an endocrinologist and cardiologist are the best way for the prevention of diabetic complications and comorbidity.

scholarly journals The result of treadmill test in asymptomatic type 2 diabetes mellitus

2017 ◽  
Vol 3 (6) ◽  
pp. 166 ◽  
Author(s):  
Anil Shrinivasrao Joshi ◽  
Chandrakant Gunaji Lahane ◽  
Akshay Arvind Kashid
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Early Detection ◽  
Diabetic Patients ◽  
Cross Sectional ◽  
Duration Of Diabetes ◽  
Asymptomatic Patients ◽  
Cardiovascular Morbidity And Mortality

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">To study the prevalence of silent myocardial ischaemia in asymptomatic patients with type 2 DM</span>.</p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">The present study was conducted in the Govt. Medical College and Hospital Aurangabad. During December 2012 to November 2014 with 50 patients. It was two year cross sectional study with the patients of asymptomatic type 2 diabetes mellitus without clinical and electrocardiographic evidence of coronary artery disease. </span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">12 (24%) out of 50 subjects had positive TMT. It correlated with years of duration of diabetes (9 positive TMT cases with duration of diabetes more than 10 years). 5 (25%) out of 20 had serum cholesterol levels &gt;240, Number of positive TMT were higher in patients with LDL &gt;160 [5 (25%) out of 20]</span>.</p><p class="abstract"><strong>Conclusions:</strong> <span lang="EN-IN">Diabetic patients are at very high risk for cardiovascular morbidity and mortality. Early detection of IHD is very important so that pharmacological therapy, which may improve outcome, can be established. Tread mill exercise TMT being a non-invasive test with high safety, has an important role in early detection of IHD. It is recommended that TMT should be a part of routine management in asymptomatic patients with type II DM. </span></p>

scholarly journals Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy

Molecules ◽  
2019 ◽  
Vol 24 (15) ◽  
pp. 2857 ◽  
Author(s):  
Sun ◽  
Wu ◽  
Cao ◽  
Zhu ◽  
Liu ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Hydrogen Sulfide ◽  
Kidney Disease ◽  
Renal Disease ◽  
Diabetic Kidney Disease ◽  
Renal Physiology ◽  
Treatment Modalities ◽  
Diabetic Patients ◽  
Diabetic Kidney ◽  
Diabetic Renal Disease

Diabetic kidney disease develops in approximately 40% of diabetic patients and is a major cause of chronic kidney diseases (CKD) and end stage kidney disease (ESKD) worldwide. Hydrogen sulfide (H2S), the third gasotransmitter after nitric oxide (NO) and carbon monoxide (CO), is synthesized in nearly all organs, including the kidney. Though studies on H2S regulation of renal physiology and pathophysiology are still in its infancy, emerging evidence shows that H2S production by renal cells is reduced under disease states and H2S donors ameliorate kidney injury. Specifically, aberrant H2S level is implicated in various renal pathological conditions including diabetic nephropathy. This review presents the roles of H2S in diabetic renal disease and the underlying mechanisms for the protective effects of H2S against diabetic renal damage. H2S may serve as fundamental strategies to treat diabetic kidney disease. These H2S treatment modalities include precursors for H2S synthesis, H2S donors, and natural plant-derived compounds. Despite accumulating evidence from experimental studies suggests the potential role of the H2S signaling pathway in the treatment of diabetic nephropathy, these results need further clinical translation. Expanding understanding of H2S in the kidney may be vital to translate H2S to be a novel therapy for diabetic renal disease.

scholarly journals Association between Food Label Unawareness and Loss of Renal Function in Diabetes: A Cross-Sectional Study in South Korea

2020 ◽  
Vol 17 (6) ◽  
pp. 1945
Author(s):  
Jae Hong Joo ◽  
Doo Woong Lee ◽  
Dong-Woo Choi ◽  
Eun-Cheol Park
Keyword(s):  
Renal Function ◽  
Renal Disease ◽  
Potential Role ◽  
Strong Association ◽  
Food Product ◽  
Diabetic Patients ◽  
Food Labels ◽  
Food Label ◽  
Cross Sectional ◽  
South Korean

Objectives: To examine sex differences in the association between food label unawareness and loss of renal function among South Korean diabetic patients aged ≥30 year and determine whether reading food labels when choosing which food products to consume plays a potential role in slowing the progression of renal disease. Methods: Data from the 2016–2017 Korea National Health and Nutrition Examination Survey were used for the analysis. Renal function was determined by the Modification of Diet in Renal Disease estimated glomerular filtration rate, and food label unawareness was defined as being unaware of the food label when choosing a food product for consumption. Multiple regression analysis was used to investigate the association between food label unawareness and loss of renal function among South Korean diabetic patients. Results: Four hundred and eighty-seven diabetic patients (men: 274; women: 213) were enrolled. Loss of renal function was associated with food label unawareness in only male diabetic patients (men: β = –10.01, standard error (SE) = 5.08, p = 0.0506; women: β = –0.30, SE = 5.14, p = 0.9528). A strong association was found between loss of renal function and food label unawareness among socially isolated male diabetic patients who lived in a one-generational household, did not have a spouse, and ate alone. Conclusion: Cultivating habits of reading food labels and inducing social facilitation may play a potential role in managing loss of renal function among male diabetic patients.

Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease

Diabetes ◽  
1996 ◽  
Vol 45 (7) ◽  
pp. 974-979 ◽  
Author(s):  
P.-H. Groop ◽  
T. Elliott ◽  
R. Friedman ◽  
G. Viberti ◽  
A. Ekstrand ◽  
...  
Keyword(s):  
Renal Disease ◽  
Diabetic Patients ◽  
Type I

scholarly journals Risk factors for non-diabetic renal disease in diabetic patients

2020 ◽  
Author(s):  
Sheila Bermejo ◽  
Ester González ◽  
Katia López-Revuelta ◽  
Meritxell Ibernon ◽  
Diana López ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Disease ◽  
Analytical Data ◽  
Multivariate Logistic Regression Analysis ◽  
Older Age ◽  
Diabetic Patients ◽  
Diabetic Renal Disease ◽  
Patients With Diabetes ◽  
Renal Prognosis ◽  
Independent Risk Factors

Abstract Background Diabetic patients with kidney disease have a high prevalence of non-diabetic renal disease (NDRD). Renal and patient survival regarding the diagnosis of diabetic nephropathy (DN) or NDRD have not been widely studied. The aim of our study is to evaluate the prevalence of NDRD in patients with diabetes and to determine the capacity of clinical and analytical data in the prediction of NDRD. In addition, we will study renal and patient prognosis according to the renal biopsy findings in patients with diabetes. Methods Retrospective multicentre observational study of renal biopsies performed in patients with diabetes from 2002 to 2014. Results In total, 832 patients were included: 621 men (74.6%), mean age of 61.7 ± 12.8 years, creatinine was 2.8 ± 2.2 mg/dL and proteinuria 2.7 (interquartile range: 1.2–5.4) g/24 h. About 39.5% (n = 329) of patients had DN, 49.6% (n = 413) NDRD and 10.8% (n = 90) mixed forms. The most frequent NDRD was nephroangiosclerosis (NAS) (n = 87, 9.3%). In the multivariate logistic regression analysis, older age [odds ratio (OR) = 1.03, 95% CI: 1.02–1.05, P &lt; 0.001], microhaematuria (OR = 1.51, 95% CI: 1.03–2.21, P = 0.033) and absence of diabetic retinopathy (DR) (OR = 0.28, 95% CI: 0.19–0.42, P &lt; 0.001) were independently associated with NDRD. Kaplan–Meier analysis showed that patients with DN or mixed forms presented worse renal prognosis than NDRD (P &lt; 0.001) and higher mortality (P = 0.029). In multivariate Cox analyses, older age (P &lt; 0.001), higher serum creatinine (P &lt; 0.001), higher proteinuria (P &lt; 0.001), DR (P = 0.007) and DN (P &lt; 0.001) were independent risk factors for renal replacement therapy. In addition, older age (P &lt; 0.001), peripheral vascular disease (P = 0.002), higher creatinine (P = 0.01) and DN (P = 0.015) were independent risk factors for mortality. Conclusions The most frequent cause of NDRD is NAS. Elderly patients with microhaematuria and the absence of DR are the ones at risk for NDRD. Patients with DN presented worse renal prognosis and higher mortality than those with NDRD. These results suggest that in some patients with diabetes, kidney biopsy may be useful for an accurate renal diagnosis and subsequently treatment and prognosis.

scholarly journals 17β-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-β protein expression and signaling

2007 ◽  
Vol 293 (5) ◽  
pp. F1678-F1690 ◽  
Author(s):  
Alexis Dixon ◽  
Christine Maric
Keyword(s):  
Extracellular Matrix ◽  
Growth Factor ◽  
Renal Disease ◽  
Protein Expression ◽  
Transforming Growth Factor ◽  
Disease Process ◽  
Type I ◽  
Plasminogen Activator Inhibitor 1 ◽  
Diabetic Renal Disease ◽  
17Β Estradiol

We previously showed that supplementation with 17β-estradiol (E2) from the onset of diabetes attenuates the development of diabetic renal disease. The aim of the present study was to examine whether E2 can also attenuate the disease process once it has developed. The present study was performed in nondiabetic and streptozotocin-induced diabetic Sprague-Dawley rats. E2 supplementation began after 9 wk of diabetes and continued for 8 wk. Diabetes was associated with an increase in urine albumin excretion, glomerulosclerosis, tubulointerstitial fibrosis, renal cortical collagen type I and IV, laminin, plasminogen activator inhibitor-1, tissue inhibitors of metalloproteinase-1 and -2, transforming growth factor (TGF)-β, TGF-β receptor type I and II, Smad2/3, phosphorylated Smad2/3, and Smad4 protein expression, and CD68-positive cell abundance. Decreases in matrix metalloproteinase (MMP)-2 protein expression and activity and decreases in Smad6 and Smad7 protein expression were also associated with diabetes. E2 supplementation completely or partially attenuated all these changes, except Smad4 and fibronectin, on which E2 supplementation had no effect. These data suggest that E2 attenuates the progression of diabetic renal disease once it has developed by regulating extracellular matrix, TGF-β, and expression of its downstream regulatory proteins. These findings support the notion that sex hormones in general, and E2 in particular, are important regulators of renal function and may be novel targets for the treatment and prevention of diabetic renal disease.

scholarly journals SP454NON-DIABETIC RENAL DISEASE IN TYPE 2 DIABETIC PATIENTS: PREVALENCE, CLINICAL PREDICTORS ANDOUTCOMES

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii275-iii276 ◽  
Author(s):  
Siyar Erdogmus ◽  
Zeynep Kendi Celebi ◽  
Serkan Akturk ◽  
Gizem Kumru ◽  
Sim Kutlay ◽  
...  
Keyword(s):  
Renal Disease ◽  
Diabetic Patients ◽  
Clinical Predictors ◽  
Type 2 Diabetic Patients ◽  
Diabetic Renal Disease ◽  
Type 2 Diabetic

Simultaneous pancreas-kidney transplant compared with kidney transplant in Type I diabetic patients with end-stage renal disease

2001 ◽  
Vol 33 (7-8) ◽  
pp. 3494-3495 ◽  
Author(s):  
R. Pérez ◽  
M.D. Navarro ◽  
D. del Castillo ◽  
R. Santamarı́a ◽  
J. Padillo ◽  
...  
Keyword(s):  
Renal Disease ◽  
Kidney Transplant ◽  
End Stage Renal Disease ◽  
Diabetic Patients ◽  
Type I ◽  
Simultaneous Pancreas Kidney ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document